Precious Metals Annual Report and Accounts 2002 demand Turnover Operating Profit Research and Development The divisions research and development programmes are focused 4,146m 57.4m on two main areas.
Fundamental work is being undertaken on the 55.9m performance of catalysts for ammonia oxidation that is designed to improve conversion efficiencies whilst minimising the production of 3,167m unwanted by-products, which act as greenhouse gases.
Secondly, our US based medical components business is actively developing new products for use in cardiovascular devices.
These utilise the unique characteristics of platinum group metal alloys and the super-elastic properties of nitinol.
In support of this growing area, a new development cell is being established at our Pennsylvania facility, which will further reduce response times to customer requests for new medical products.
